Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.39 |
| ▸ | CDK2 | P24941 | 7/20 | 0.39 |
| ▸ | CDK1 | P06493 | 5/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23960764 | 0.79 | CNR2 (0.39) | CCNA2CDK2CDK1CCNB1CCNA1 | |
| SCHEMBL15831918 | 0.77 | XDH (0.43) | CCNA2CDK2CCNA1MCHR1 | |
| SCHEMBL15831968 | 0.77 | NOS3 (0.47) | CCNA2CDK2CDK1CCNB1CCNA1 | |
| SCHEMBL17815699 | 0.76 | MCHR1 (0.43) | CCNA2CDK2CDK1CCNB1CCNA1 | |
| SCHEMBL24498716 | 0.75 | CNR1 (0.40) | CCNA2CDK2CDK1CCNB1CCNA1 | |
| SCHEMBL15831924 | 0.73 | XDH (0.46) | CCNA2CDK2CDK1CCNB1CCNA1 | |
| SCHEMBL15831955 | 0.73 | NOS3 (0.45) | CCNA2CDK2CDK1CCNB1CCNA1 | |
| SCHEMBL15679335 | 0.72 | NOS3 (0.44) | CCNA2CDK2CDK1CCNB1CCNA1 | |
| SCHEMBL15831928 | 0.72 | XDH (0.47) | CCNA2CDK2CDK1CCNB1CCNA1 | |
| SCHEMBL23960763 | 0.72 | CNR2 (0.37) | TRPV1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230147428-A1 | BENZIMIDAZOLONE-BASED CINNAMAMIDE DERIVATIVE AS TRPV1 ANTAGONIST AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF PAIN CONTAINING SAME AS ACTIVE INGREDIENT | JMACKEM CO., LTD (KR) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230147428-A1 | BENZIMIDAZOLONE-BASED CINNAMAMIDE DERIVATIVE AS TRPV1 ANTAGONIST AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF PAIN CONTAINING SAME AS ACTIVE INGREDIENT | TRPV1, TRPA1, TRPV5 | TRPV1 1/4885CCNA2 4338/4885CDK2 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.